Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.54 - $4.94
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.03M
Enterprise Value$12.56M
Total Cash (Recent Filing)$441.00K
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding3,609,471
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap6.18
Enterprise Value/Revenue11.34
Enterprise Value/Gross Profit12.39
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Recurring, Usage-based Revenue ModelA usage-based revenue model tied to per-procedure fees, disposables and service contracts creates durable, repeatable revenue as installed VIVO systems generate ongoing procedures. As hospital adoption and procedure volumes grow, this model supports predictable cash flow and improves long-term unit economics.
Strong Reported Revenue GrowthVery high percentage revenue growth off a low base signals early commercial traction for VIVO. If multi-period adoption continues, these trends can convert into sustainable revenue expansion, enabling the company to leverage fixed costs and improve gross and operating margins over the medium term.
Near-term Liquidity From Preferred RaiseThe Series C-2 preferred stock raise provides tangible near-term runway to fund working capital and commercialization efforts. This additional liquidity reduces immediate financing pressure, allowing management time to execute sales, distribution and adoption initiatives that are critical to scaling revenue over the next several months.
Bears Say
Persistent Operating Cash BurnSustained negative operating and free cash flow of roughly -$8.7M TTM signifies ongoing cash consumption to fund operations. Unless revenue conversion accelerates meaningfully or costs are reduced, the company will remain dependent on external financing, raising dilution and execution risk for its commercial plan.
Very Small Revenue Base Vs Extreme LossesA tiny revenue base alongside extreme negative EBIT and net margins indicates the current cost structure is far ahead of commercial scale. This creates a structural challenge: the company must materially increase procedure volumes and VIVO deployments to approach breakeven, a multiperiod operational hurdle.
Rising Leverage And Dilution From Structured FinancingsDeteriorating balance-sheet trajectory, rising debt and reliance on convertible preferreds and equity-for-acquisition increase capital structure complexity. This raises dilution risk, may constrain strategic flexibility, and can increase financing costs and governance friction as the company seeks additional capital to fund growth.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.54 and its highest was $4.94 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.03M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 29 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 3,609,471 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.
Technical Analysis
Ownership Overview
0.39%
Insiders
0.23% Mutual Funds
<0.01% Other Institutional Investors
99.38% Public Companies and
Individual Investors